Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
Archer DF, Goldstein SR, Simon JA, Waldbaum AS, Sussman SA, Altomare C, Zhu J, Yoshida Y, Schaffer S, Soulban G. Archer DF, et al. Among authors: waldbaum as. Menopause. 2019 Jan 28;26(6):611-621. doi: 10.1097/GME.0000000000001292. Menopause. 2019. PMID: 30694917 Free PMC article. Clinical Trial.
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É; VVA Prasterone Research Group. Labrie F, et al. Menopause. 2016 Mar;23(3):243-56. doi: 10.1097/GME.0000000000000571. Menopause. 2016. PMID: 26731686 Clinical Trial.
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Labrie F, Archer DF, Bouchard C, Girard G, Ayotte N, Gallagher JC, Cusan L, Baron M, Blouin F, Waldbaum AS, Koltun W, Portman DJ, Côté I, Lavoie L, Beauregard A, Labrie C, Martel C, Balser J, Moyneur É; Members of the VVA Prasterone Group. Labrie F, et al. Among authors: waldbaum as. Maturitas. 2015 May;81(1):46-56. doi: 10.1016/j.maturitas.2015.02.005. Epub 2015 Feb 16. Maturitas. 2015. PMID: 25771041 Clinical Trial.
Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
Bouchard C, Labrie F, Archer DF, Portman DJ, Koltun W, Elfassi É, Grainger DA, Ayotte N, Cooper TA, Martens M, Waldbaum AS, Labrie C, Côté I, Lavoie L, Martel C, Balser J; VVA Prasterone Group. Bouchard C, et al. Among authors: waldbaum as. Climacteric. 2015;18(4):590-607. doi: 10.3109/13697137.2014.992012. Epub 2015 Mar 3. Climacteric. 2015. PMID: 25511551 Clinical Trial.
Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
Santoro N, Waldbaum A, Lederman S, Kroll R, Fraser GL, Lademacher C, Skillern L, Young J, Ramael S. Santoro N, et al. Menopause. 2020 Dec;27(12):1350-1356. doi: 10.1097/GME.0000000000001621. Menopause. 2020. PMID: 32769757 Free PMC article. Clinical Trial.
Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis.
Chavoustie SE, Carter BA, Waldbaum AS, Donders GGG, Peters KH, Schwebke JR, Paull JRA, Price CF, Castellarnau A, McCloud P, Kinghorn GR. Chavoustie SE, et al. Among authors: waldbaum as. Eur J Obstet Gynecol Reprod Biol. 2020 Feb;245:13-18. doi: 10.1016/j.ejogrb.2019.11.032. Epub 2019 Nov 28. Eur J Obstet Gynecol Reprod Biol. 2020. PMID: 31812702 Free article. Clinical Trial.
20 results